The patents relate to the company’s ability to create, develop and manufacture antibodies based on its dynamic cross linking (DXL) technology platform. The new patents name InNexus scientists as inventors and are solely owned by InNexus.
Jeff Morhet, chairman and CEO of InNexus, said: “These patent grants demonstrate our commitment to providing real value to our shareholders by protecting and ensuring exclusivity of our DXL technology.
“Our patent portfolio provides potential for future royalty and licensing deals or outright sales of our expanding and maturing family of DXL preclinical candidates.”